Below are the most recent publications written about "Hypolipidemic Agents" by people in Profiles.
-
Koschinsky ML, Bajaj A, Boffa MB, Dixon DL, Ferdinand KC, Gidding SS, Gill EA, Jacobson TA, Michos ED, Safarova MS, Soffer DE, Taub PR, Wilkinson MJ, Wilson DP, Ballantyne CM. A focused update to the 2019 NLA scientific statement on use of lipoprotein(a) in clinical practice. J Clin Lipidol. 2024 May-Jun; 18(3):e308-e319.
-
Patrick WL, Khurshan F, Bavaria JE, Zhao Y, Groeneveld PW, Yarlagadda S, Rosen JL, Grimm JC, Szeto WY, Desai ND. National Adherence to Medical Management of Aortic Aneurysms. Am J Med. 2022 10; 135(10):1202-1212.e4.
-
Karalis DG. Editorial commentary: Advances in the management of dyslipidemia: The future is bright, but what we do today is what matters most. Trends Cardiovasc Med. 2021 10; 31(7):425-426.
-
Khan SU, Khan MU, Valavoor S, Khan MS, Okunrintemi V, Mamas MA, Leucker TM, Blaha MJ, Michos ED. Association of lowering apolipoprotein B with cardiovascular outcomes across various lipid-lowering therapies: Systematic review and meta-analysis of trials. Eur J Prev Cardiol. 2020 08; 27(12):1255-1268.
-
Li YR, Ro V, Steel L, Carrigan E, Nguyen J, Williams A, So A, Tchou J. Impact of long-term lipid-lowering therapy on clinical outcomes in breast cancer. Breast Cancer Res Treat. 2019 Aug; 176(3):669-677.
-
Wright AK, Kontopantelis E, Emsley R, Buchan I, Mamas MA, Sattar N, Ashcroft DM, Rutter MK. Cardiovascular Risk and Risk Factor Management in Type 2 Diabetes Mellitus. Circulation. 2019 06 11; 139(24):2742-2753.
-
Friedrich DA, Karalis DG, Aspry KE, Martin SS, Guyton JR. JCL roundtable: Lipid treatment targets. J Clin Lipidol. 2019 Mar - Apr; 13(2):223-230.
-
Robinson JG, Williams KJ, Gidding S, Bor?n J, Tabas I, Fisher EA, Packard C, Pencina M, Fayad ZA, Mani V, Rye KA, Nordestgaard BG, Tybj?rg-Hansen A, Douglas PS, Nicholls SJ, Pagidipati N, Sniderman A. Eradicating the Burden of Atherosclerotic Cardiovascular Disease by Lowering Apolipoprotein B Lipoproteins Earlier in Life. J Am Heart Assoc. 2018 10 16; 7(20):e009778.
-
Fink HA, Jutkowitz E, McCarten JR, Hemmy LS, Butler M, Davila H, Ratner E, Calvert C, Barclay TR, Brasure M, Nelson VA, Kane RL. Pharmacologic Interventions to Prevent Cognitive Decline, Mild Cognitive Impairment, and Clinical Alzheimer-Type Dementia: A Systematic Review. Ann Intern Med. 2018 01 02; 168(1):39-51.
-
Hess GP, Natarajan P, Faridi KF, Fievitz A, Valsdottir L, Yeh RW. Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor Therapy: Payer Approvals and Rejections, and Patient Characteristics for Successful Prescribing. Circulation. 2017 Dec 05; 136(23):2210-2219.